Zobrazeno 1 - 10
of 546
pro vyhledávání: '"Dan H, Barouch"'
Autor:
Boris Julg, Kathryn E. Stephenson, Frank Tomaka, Stephen R. Walsh, C. Sabrina Tan, Ludo Lavreys, Michal Sarnecki, Jessica L. Ansel, Diane G. Kanjilal, Kate Jaegle, Tessa Speidel, Joseph P. Nkolola, Erica N. Borducchi, Esmee Braams, Laura Pattacini, Eleanor Burgess, Shlomi Ilan, Yannic Bartsch, Katherine E. Yanosick, Michael S. Seaman, Daniel J. Stieh, Janine van Duijn, Wouter Willems, Merlin L. Robb, Nelson L. Michael, Bruce D. Walker, Maria Grazia Pau, Hanneke Schuitemaker, Dan H. Barouch
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-10 (2024)
Abstract Mosaic HIV-1 vaccines have been shown to elicit robust humoral and cellular immune responses in people living with HIV-1 (PLWH), that had started antiretroviral therapy (ART) during acute infection. We evaluated the safety and immunogenicity
Externí odkaz:
https://doaj.org/article/59601776515445b699048f239a5f3f75
Publikováno v:
Journal of the International AIDS Society, Vol 27, Iss 5, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/0ec79e78f93d47f1bd6912ee6a3be1f5
Autor:
Catherine Jacob-Dolan, Michelle Lifton, Olivia C. Powers, Jessica Miller, Nicole P. Hachmann, Mya Vu, Nehalee Surve, Camille R. Mazurek, Jana L. Fisher, Stefanie Rodrigues, Robert C. Patio, Trisha Anand, Mathieu Le Gars, Jerald Sadoff, Aaron G. Schmidt, Dan H. Barouch
Publikováno v:
iScience, Vol 27, Iss 5, Pp 109716- (2024)
Summary: The viral vector-based COVID-19 vaccine Ad26.COV2.S has been recommended by the WHO since 2021 and has been administered to over 200 million people. Prior studies have shown that Ad26.COV2.S induces durable neutralizing antibodies (NAbs) tha
Externí odkaz:
https://doaj.org/article/319b65fba338482abc0eb9e090cc8de1
Publikováno v:
PLoS Computational Biology, Vol 20, Iss 3, p e1011518 (2024)
PGT121 is a broadly neutralizing antibody in clinical development for the treatment and prevention of HIV-1 infection via passive administration. PGT121 targets the HIV-1 V3-glycan and demonstrated potent antiviral activity in a phase I clinical tria
Externí odkaz:
https://doaj.org/article/d7081fcfeb604410b37e85281ccd19ab
Autor:
Malika Aid, Kathryn E. Stephenson, Ai-ris Y. Collier, Joseph P. Nkolola, James V. Michael, Steven E. McKenzie, Dan H. Barouch
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract Thrombosis with thrombocytopenia syndrome (TTS) is a rare but potentially severe adverse event following immunization with adenovirus vector-based COVID-19 vaccines such as Ad26.COV2.S (Janssen) and ChAdOx1 (AstraZeneca). However, no case of
Externí odkaz:
https://doaj.org/article/9e0279f50cd949b9be8538aa12037484
Autor:
Dan H Barouch, Yi Wang, Mark P Rubinstein, Zihai Li, Anqi Li, Sarah Reisinger, Peter G Shields, Qin Ma, No-Joon Song, Dongjun Chung, Karthik B Chakravarthy, Chelsea Bolyard, Hyeongseon Jeon, Kelsi Reynolds, Kevin P Weller, Sizun Jiang, Eugene M Oltz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant is highly transmissible and evades pre-established immunity. Messenger RNA (mRNA) vaccination against ancestral strain spike protein can induce intact T-cell
Externí odkaz:
https://doaj.org/article/a52a3aaab70c4bc4b814b6816e637492
Autor:
Bryan T. Mayer, Lily Zhang, Allan C. deCamp, Chenchen Yu, Alicia Sato, Heather Angier, Kelly E. Seaton, Nicole Yates, Julie E. Ledgerwood, Kenneth Mayer, Marina Caskey, Michel Nussenzweig, Kathryn Stephenson, Boris Julg, Dan H. Barouch, Magdalena E. Sobieszczyk, Srilatha Edupuganti, Colleen F. Kelley, M. Juliana McElrath, Huub C. Gelderblom, Michael Pensiero, Adrian McDermott, Lucio Gama, Richard A. Koup, Peter B. Gilbert, Myron S. Cohen, Lawrence Corey, Ollivier Hyrien, Georgia D. Tomaras, Yunda Huang
Publikováno v:
Pharmaceutics, Vol 16, Iss 5, p 594 (2024)
Monoclonal antibodies are commonly engineered with an introduction of Met428Leu and Asn434Ser, known as the LS mutation, in the fragment crystallizable region to improve pharmacokinetic profiles. The LS mutation delays antibody clearance by enhancing
Externí odkaz:
https://doaj.org/article/34ca5d472d9b40e7a742cd8a83e9c15b
Autor:
Laura Solforosi, Lea M. M. Costes, Jeroen T. B. M. Tolboom, Katherine McMahan, Tochi Anioke, David Hope, Tetyana Murdza, Michaela Sciacca, Emily Bouffard, Julia Barrett, Cindy Wu, Nicole Hachmann, Jessica Miller, Jingyou Yu, Xuan He, Catherine Jacob-Dolan, Sietske K. Rosendahl Huber, Liesbeth Dekking, Ronnie Chamanza, Ying Choi, Karin Feddes-de Boer, Dan H. Barouch, Hanneke Schuitemaker, Roland C. Zahn, Frank Wegmann
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)
Variant booster vaccines are a strategy to improve protection against SARS-CoV-2. Here, the authors find that both Wuhan-Hu-1-based Ad26.COV2.S or an Omicron-adapted booster vaccine provide robust immune responses and protection against Omicron in NH
Externí odkaz:
https://doaj.org/article/48f5d6d725c04fbe926ebad22c4e7481
Autor:
Catherine Jacob-Dolan, Jingyou Yu, Katherine McMahan, Victoria Giffin, Abishek Chandrashekar, Amanda J. Martinot, Tochi Anioke, Olivia C. Powers, Kevin Hall, David Hope, Jessica Miller, Nichole P. Hachmann, Benjamin Chung, Sarah Gardner, Daniel Sellers, Julia Barrett, Mark G. Lewis, Hanne Andersen, Harry Kleanthous, Ki-Woen Seo, Su Jeen Lee, Yong Wook Park, Hun Kim, Dan H. Barouch
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-9 (2023)
Abstract Despite the availability of several effective SARS-CoV-2 vaccines, additional vaccines will be required for optimal global vaccination. In this study, we investigate the immunogenicity and protective efficacy of the GBP510 protein subunit va
Externí odkaz:
https://doaj.org/article/2859911f0f034613a627935fa3b765b4
Autor:
Etsuro Nanishi, Francesco Borriello, Hyuk-Soo Seo, Timothy R. O’Meara, Marisa E. McGrath, Yoshine Saito, Jing Chen, Joann Diray-Arce, Kijun Song, Andrew Z. Xu, Soumik Barman, Manisha Menon, Danica Dong, Timothy M. Caradonna, Jared Feldman, Blake M. Hauser, Aaron G. Schmidt, Lindsey R. Baden, Robert K. Ernst, Carly Dillen, Jingyou Yu, Aiquan Chang, Luuk Hilgers, Peter Paul Platenburg, Sirano Dhe-Paganon, Dan H. Barouch, Al Ozonoff, Ivan Zanoni, Matthew B. Frieman, David J. Dowling, Ofer Levy
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-16 (2023)
Abstract Development of SARS-CoV-2 vaccines that protect vulnerable populations is a public health priority. Here, we took a systematic and iterative approach by testing several adjuvants and SARS-CoV-2 antigens to identify a combination that elicits
Externí odkaz:
https://doaj.org/article/1cc5213015424ab48d02bcd22247ff42